PATRYS LIMITED (ASX: PAB)
Health care · News and insights
Price unavailable
Latest PAB announcements
Announcement Insights
Patrys Clears First RLS-2202 Safety Review, With Further Dosing Dependent On Trial-Batch Release
Patrys has advanced its Phase 1a RLS-2202 trial after the first cohort completed dosing and follow-up and a safety review recommended moving to the next cohort. The company is targeting final participant dosing in the December quarter, subject to release of the clinical trial batch; it ended the quarter with approximately A$2 million in cash and anticipates an approximately A$620,000 R&D tax incentive refund. Separately, Patrys appointed RSM Australia Partners after BDO resigned with ASIC consent, with shareholders to consider ratification at the next AGM.
Updated 11 Nov 2026, 06:49 PM Sydney time
Sources
Change of AuditorApplication for quotation of securities - PABCleansing NoticeChange of Director's Interest Notice x2Change in substantial holdingNotice of Annual General Meeting/Proxy FormLetter to Shareholders - Annual General MeetingAppendix 4C - Quarterly - 30 September 2026Comments
2026-11-11 · Health care
PAB: $0.023 -4.17% · MC: $8M
Patrys Limited has appointed RSM Australia Partners as auditor, effective immediately, after BDO Audit resigned with ASIC consent. The board said the change followed a review of its external audit arrangements and fee structure; shareholders will be asked to ratify the appointment at the next AGM.
Updated 2026-11-11 18:38
Sources
Change of AuditorComments
2026-11-09 · Health care
PAB: $0.020 -9.09% · MC: $8M
Patrys issued 34 million shares after performance rights converted, taking its ordinary shares on issue to over 708 million. Leanne Kite’s voting power increased from 5.75% to 6.87%, following the conversion of vested rights into shares; the director notices also record similar conversions for Dino Cercarelli.
Updated 2026-11-09 18:13
Sources
Application for quotation of securities - PABChange of Director's Interest Notice x2Cleansing NoticeChange in substantial holdingComments
2026-10-30 · Health care
PAB: $0.024 -4.00% · MC: $8M
Patrys will hold its annual general meeting on 30 November, with shareholders asked to vote on director elections and approval for a proposed issue of shares and options to director Brian Leedman. The meeting will also consider the annual report and remuneration report for the year ended 30 June 2026.
Updated 2026-10-30 13:29
Sources
Notice of Annual General Meeting/Proxy FormLetter to Shareholders - Annual General MeetingComments
2026-10-29 · Health care
PAB: $0.025 +0.00% · MC: $8M
Patrys completed dosing and follow-up for all participants in the first cohort of its Phase 1a RLS-2202 trial, and a post-quarter safety review recommended advancing to the next cohort. The company is targeting final participant dosing in the December quarter, subject to release of the clinical trial batch; it also agreed Yale will receive the deoxymab intellectual property, with Patrys entitled to half of Yale’s directly attributable commercialisation revenue. Patrys ended the quarter with approximately A$2 million in cash and anticipates an R&D tax incentive refund of approximately A$620,000.
Updated 2026-10-29 11:16
Sources
Appendix 4C - Quarterly - 30 September 2026Comments
Comments